Literature DB >> 26264901

[Headache. Current status of research and treatment].

A Straube1, C Gaul2.   

Abstract

The starting point for German headache research and clinical education was the engagement of D. Soyka in the 1970s, which enabled the foundation of the German Headache Society (DMKG) on 28 June 1979 and, some years later, the founding congress of the International Headache Society (IHS) in Munich 1982. As a result of these activities, in 1988 the first international classification of headache disorders was published. This classification was one of the major milestones in the development of basic as well as clinical headache research. In the following years, epidemiological studies all over the world showed a 1-year prevalence for headache of approximately 60%, making headaches one of the most frequent medical complaints. Basic research showed an involvement of serotonergic mechanisms in migraine pain and triptans were one of the first drugs designed to influence these mechanisms. Functional brain imaging studies in migraine patients further showed a cyclic modulation of the activity of brainstem areas independent of the current pain state. Various research groups were involved in the clarification of the role of calcitonin gene-related peptide (CGRP) in migraine and cluster headache. A specific development in the German headache scene is the establishment of integrated headache centers and reflects the primarily multimodal treatment approach in Germany which contrasts with the settings in other countries. These successful developments are increasingly being undermined by the fact that the low financial support of headache research, for example, by the German science council is causing a decreasing interest in headache research, with the consequence that the clinical education of students as well as young medical doctors shows increasing deficits. The consequence for the future will be a deficit in the clinical care of the population.

Entities:  

Keywords:  Classification, headaches; Medical education, clinical; Medical education, undergraduate; Migraine; Research, clinical

Mesh:

Substances:

Year:  2015        PMID: 26264901     DOI: 10.1007/s00482-015-0040-2

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  44 in total

Review 1.  Epidemiology of headache in Europe.

Authors:  L J Stovner; J-A Zwart; K Hagen; G M Terwindt; J Pascual
Journal:  Eur J Neurol       Date:  2006-04       Impact factor: 6.089

2.  Headache prevalence among adolescents--the German DMKG headache study.

Authors:  K Fendrich; M Vennemann; V Pfaffenrath; S Evers; A May; K Berger; W Hoffmann
Journal:  Cephalalgia       Date:  2007-04       Impact factor: 6.292

3.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

Review 4.  Sumatriptan in acute migraine: pharmacology and review of world experience.

Authors:  S J Peroutka
Journal:  Headache       Date:  1990       Impact factor: 5.887

5.  The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study.

Authors:  H C Diener; V Pfaffenrath; L Pageler; H Peil; B Aicher
Journal:  Cephalalgia       Date:  2005-10       Impact factor: 6.292

6.  Gray matter volume reduction reflects chronic pain in trigeminal neuralgia.

Authors:  Mark Obermann; Rea Rodriguez-Raecke; Steffen Naegel; Dagny Holle; Daniel Mueller; Min-Suk Yoon; Nina Theysohn; Sebastian Blex; Hans-Christoph Diener; Zaza Katsarava
Journal:  Neuroimage       Date:  2013-02-26       Impact factor: 6.556

7.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

8.  Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine.

Authors:  A Doenicke; J Brand; V L Perrin
Journal:  Lancet       Date:  1988-06-11       Impact factor: 79.321

9.  Regional variations in the prevalence of migraine and tension-type headache applying the new IHS criteria: the German DMKG Headache Study.

Authors:  V Pfaffenrath; K Fendrich; M Vennemann; C Meisinger; K-H Ladwig; S Evers; A Straube; W Hoffmann; K Berger
Journal:  Cephalalgia       Date:  2008-09-02       Impact factor: 6.292

Review 10.  Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache.

Authors:  Charly Gaul; Corine M Visscher; Rhia Bhola; Marjolijn J Sorbi; Federica Galli; Annette V Rasmussen; Rigmor Jensen
Journal:  J Headache Pain       Date:  2011-07-21       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.